Icecure Medical’s Earnings Outlook

Icecure Medical (NASDAQ:ICCM) is set to give its latest quarterly earnings report on Wednesday, 2023-03-29. Here’s what investors…

Icecure Medical (NASDAQ:ICCM) is set to give its latest quarterly earnings report on Wednesday, 2023-03-29. Here’s what investors need to know before the announcement.

Analysts estimate that Icecure Medical will report an earnings per share (EPS) of $-0.11.

Icecure Medical bulls will hope to hear the company announce they’ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Here’s a look at Icecure Medical’s past performance and the resulting price change:

Quarter H1 2022 FY 2021
EPS Estimate
EPS Actual -0.24 -0.35
Price Change % -0.99% -1.25%

Stock Performance

Shares of Icecure Medical were trading at $1.12 as of March 27. Over the last 52-week period, shares are down 48.55%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release.

To track all earnings releases for Icecure Medical visit their earnings calendar on our site.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Hemp-Focused Wellness Co. Moves Closer To Profitability, Reports Flat 2023 Revenue, Increase In Gross Profit

Hemp-focused consumer wellness company CV Sciences, Inc. (OTCQB: CVSI) announced on Thursday its financial results for the year ended Dec. 31, 2023. The San Diego-based company reported a gross margin of 44.3% for fiscal year 2023, representing an improvement from 34.2% for 2022. For the fourth quarter gross margin was 45.8%, representing a sequential improvement from 45.1% in the third quarter. "Our 2023 progress demonstrates our continuous commitment to innovation and cost-efficient execution as we move closer to profitability and positive cash flow," Joseph Dowling, CEO of CV Sciences, said. "As the CBD category consolidates, we have increased our market share in key sales channels, including the natural product retail channel. We will continue to focus our resources on new product development, as evidenced by our pet line expansion with our recent launch of pet chews for hip and joint health and calming care."

CVSI